SARS-CoV-2 3CLpro-IN-5

• UNSPSC Description:

  SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CLpro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CLpro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19)[1].

• Target Antigen:

  SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/sars-cov-2-3clpro-in-5.html

• Solubility:

  10 mM in DMSO

• Smiles:

  FC1=CC=CC2=C1C=C(C(N[C@H](C(NN(C([C@@](F)([H])Cl)=O)C[C@H]3C(NCC3)=O)=O)CC(C)C)=O)N2

• Molecular Weight:

  497.92

• References & Citations:

  [1]Yuya Hirose, et al. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. J Med Chem

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2913186-57-7